Multiple Sclerosis is a disease that has the body’s immunity system attacking, and disabling the central nervous system (CNS). A clinical trial study named on the disease dubbed, HALT-MS, revealed that a high dosage of drugs that suppress the strength of the immunity system, coupled with a blood stem transplant, increase the chances of the sustained remission.
The NIAID, which is connected to the National Institute of Health sponsored the trial. It was coordinated by ITN which is funded by NIAID.
The trail study noted that sixty-nine percent of the people that participated in the pilot study did not experience progressive disability, new brain lesions or even relapse of the MS symptoms, five years after receiving the treatment.
The treatment is known as HDIT/HCT i.e. therapy that inhibits the activity in the immune system, and autologous cell transplanting in large doses. The study also observed that after going through the HDIT/HCT treatment, the participants did not need to continue taking any medication.
The trial treatment is centered on reducing the activity of the disease and eliminating the possibility of the CNS being disabled by this activity. This was done by the removal of the disease-inducing cells and rebooting the immune system by transplanting a participant’s blood-making stem cells.
The study has made tremendous success in stabilizing MS to date and reveal that HDIT/HCT can become a potential solution to people with relapsing-remitting multiple sclerosis.
Shiva Gopal Vasishta
Dr. Shiva Gopal Vasishta is well known for his specialty and contributions in Neurology globally. Dr. Gopal is also licensed to practice Psychiatry in Voorhees, New Jersey. He attained his medical degree from Government Medical College in 1979.
Dr. Shiva Gopal Vasishta went through his residency at Boston City Hospital and has over 40 years of medical excellence to date.
He currently operates his practice at Eastern Neurodiagnostic Associate. Dr. Shiva Gopal Vasishta is recognized for his affiliations with Kennedy Health System Cherry Hill where he is making significant contributions to the neurological field.